Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420641 | 0.85 | GRIA2 (0.44) | FFAR4GRM5GRM4GRIA2AXL | |
| SCHEMBL15420755 | 0.84 | GRIA2 (0.43) | FFAR4GRM5GRM4GRIA2AXL | |
| SCHEMBL15420427 | 0.84 | GRIA2 (0.41) | FFAR4GRM5GRM4GRIA2AXL | |
| SCHEMBL15420619 | 0.84 | FFAR4 (0.41) | FFAR4DGAT1GRM4 | |
| SCHEMBL15420322 | 0.79 | GRM5 (0.41) | DGAT1GRM5GRM4GRIA2HDAC1 | |
| SCHEMBL15420397 | 0.79 | GRIA2 (0.42) | FFAR4DGAT1GRM5GRIA2AXL | |
| SCHEMBL12986813 | 0.79 | GRIA2 (0.42) | FFAR4DGAT1GRM5GRIA2AXL | |
| SCHEMBL15420028 | 0.79 | GRIA2 (0.42) | FFAR4DGAT1GRM5GRIA2AXL | |
| SCHEMBL12987995 | 0.79 | GRIA2 (0.42) | FFAR4DGAT1GRM5GRIA2AXL | |
| SCHEMBL12986811 | 0.79 | GRIA2 (0.42) | FFAR4DGAT1GRM5GRIA2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | FFAR4 277/4885DGAT1 2937/4885GRM5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.